Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-29T18:04:22.188Z Has data issue: false hasContentIssue false

Cardiovascular manifestations of Hutchinson–Gilford progeria syndrome

Published online by Cambridge University Press:  13 January 2022

Andreia Palma*
Affiliation:
Department of Paediatric Cardiology, Referral Centre for Congenital Cardiac Defects, CHUC, Portugal, Coimbra, Portugal
Patrícia V. Silva
Affiliation:
Department of Paediatric Cardiology, Referral Centre for Congenital Cardiac Defects, CHUC, Portugal, Coimbra, Portugal
António Pires
Affiliation:
Department of Paediatric Cardiology, Referral Centre for Congenital Cardiac Defects, CHUC, Portugal, Coimbra, Portugal
*
Author for correspondence: Andreia Palma, Hospital Pediátrico de Coimbra, Avenida Dr. Afonso Romão, 3000-602 Coimbra, Portugal. Tel:+351965067190/ +351239488700. E-mail: [email protected]

Abstract

Cardiovascular complications are the most frequent cause of death in patients with the HutchinsonGilford progeria syndrome. However, due to its rarity, studying the course of cardiac abnormalities has been a challenge. The cardiovascular phenotype helps to provide greater insight into the natural history of these abnormalities.

Type
Brief Report
Copyright
© The Author(s), 2022. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Merideth, MA, Gordon, LB, Clauss, S, et al. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med 2008; 358: 592604. DOI 10.1056/NEJMoa0706898.CrossRefGoogle ScholarPubMed
Gonzalo, S, Kreienkamp, G, Askjaer. Hutchinson-Gilford progeria syndrome: a premature aging disease caused by LMNA gene mutations. Ageing Res Rev 2017; 3: 1829. DOI 10.1016/j.arr.2016.06.007.CrossRefGoogle Scholar
Prakash, A, Gordon, LB, Kleinman, ME, et al. Cardiac abnormalities in patients with Hutchinson-Gilford progeria syndrome. JAMA 2018; 3: 326334. DOI 10.1001/jamacardio.2017.5235.Google ScholarPubMed
Sluysmans, T, Colan, SD. Theoretical and empirical derivation of cardiovascular allometric relationships in children. J Appl Physiol 1985 2005; 99: 445457. DOI 10.1152/japplphysiol.01144.2004.CrossRefGoogle ScholarPubMed
Zhao, XN, Song, HP, Yang, F, et al. Ultrasonic characteristics of cardiovascular changes in children with Hutchinson-Gilford progeria syndrome: a comparative study with normal children and aging people. Biomed Res Int 2020; 2020: 18. DOI 10.1155/2020/9631851.Google ScholarPubMed
Lonafarnib, Dhillon S. First approval. Drugs 2021; 81: 283289. DOI 10.1007/s40265-020-01464-z.Google Scholar
Gordon, LB, Shappell, H, Massaro, J, et al. Association of lonafarnib treatment vs no treatment with mortality rate in patients with Hutchinson-Gilford progeria syndrome. JAMA 2018; 319: 16871695. DOI 10.1001/jama.2018.3264.CrossRefGoogle ScholarPubMed
Musumeci, F, Cammardella, AG, Lio, A, et al. Hutchinson-Gilford progeria syndrome and severe aortic stenosis: a new hope for treatment. Ann Thorac Surg 2020; 110: e365e367. DOI 10.1016/j.athoracsur.2020.03.067.CrossRefGoogle ScholarPubMed
Ha, JW, Shim, WH, Chung, NS. Cardiovascular findings of Hutchinson-Gilford syndrome - a doppler and two-dimensional echocardiographic study. Yonsei Med J 1993; 34: 352355. DOI 10.3349/ymj.1993.34.4.352.CrossRefGoogle ScholarPubMed
Makous, N, Friedman, S, Yakovac, W, et al. Cardiovascular manifestations in progeria. report of clinical and pathologic findings in a patient with severe arteriosclerotic heart disease and aortic stenosis. Am Heart J 1962; 64: 334346. DOI 10.1016/0002-8703(62)90148-5.CrossRefGoogle Scholar